Note: Descriptions are shown in the official language in which they were submitted.
CA 02497261 2005-02-28
WO 2004/021071 PCT/CA2003/001324
1
A DEVICE FOR THE PREVENTION OF MELATONIN
SUPPRESSION BY LIGHT AT NIGHT
FIELD OF THE INVENTION
The present invention relates to a device for inhibiting melatonin suppressing
light and in
particular to a device for preventing the suppression of melatonin levels that
normally occurs
upon exposure to broad spectrum wavelength light at night.
BACKGROUND OF THE INVENTION
A form of enviromnental pollution that has attracted recent interest is light
pollution, in the form
of light trespass, up-light that obscures the night sky and glare or side-
light that blinds at night. In
addition, there is recent evidence that exposure to light at night may have
detrimental effects on
the health of both animals and humans. Melatonin secretion from the pineal
gland has been
implicated in the etiology of these adverse health effects of night light
exposure.
Melatonin, N-acetyl-5-inetlioxytiyptaniine, is the principal hormone of the
pineal gland, and
mediates many biological functions, particularly those that are controlled by
the duration of light
and darkness. Melatonin is synthesized from tryptophan through serotonin,
which is N-
acetylated by the enzyme n-acetyl transferase or NAT, and then methylated by
hydroxyindol-O-
methyl transferase. The enzyme NAT is the rate-limiting enzyme for the
synthesis of melatonin,
and is increased by norepinephrine at the sympathetic nerve endings in the
pineal gland.
Norepinephrine is released at night or in the dark phase from these nerve
endings. Thus,
melatonin secretion is controlled mainly by light and dark phases.
The secretion of melatonin in the human is circadian, with high levels at
night and low levels in
the morning. The light/dark cycle is a pervasive and prominent Zeitgeber of
the regulation of
circadian timing system: in the presence of light, the output from the Retino-
Hypothalamic Tract
inhibits the melatonin synthesis, whereas darkness stimulates it.
Like myriads of circadian rhythms in mammals (drinking and feeding, wake-sleep
cycle,
temperature, cortisol, corticosterone etc.), the melatonin rhythm is generated
by an endogenous
pacemaker located in the anterior hypothalamic suprachiasmatic nuclei (SCN).
In humans, the
circadian rhythm for the release of melatonin is closely synchronized with the
habitual hours of
sleep. Typically, melatonin secretion starts at 2100 hrs (9pm) and increases
to a peak at 0200 hr
CA 02497261 2005-02-28
WO 2004/021071 PCT/CA2003/001324
2
(2am) and then falls to a nadir about 0600 hr (6am). However, a curious
characteristic of the
melatonin rhythm is that it can be acutely interrupted by exposure to light.
It has been shown that
light exposure in the early subjective night delays the timing of the
circadian clock while light
exposure in the late subjective night advances the timing of the clock.
Exposure to light at either
time suppresses melatonin secretion.
The melatonin secretion rhythm changes for shift workers, who eventually have
a different rise
and fall depending on their "normal" time of resting. Travelers through
different time zones
suffer from so-called jet lag that in most part is related to their circadian
rhythm of melatonin
being out of synchrony with the local clock time. Light suppression of
melatonin can occur very
quickly in the dark phase with secretion returning rapidly following the
cessation of light.
Exposure to light in the middle of the dark period results in suppression of
melatonin levels of up
to 85%.
All of melatonin's functions have yet to be defined, but this hormone appears
to: 1) Synchronize
the circadian rhythms of the body, 2) Stimulate immune function, 3) Inhibit
growth of cancer
cells in vitro, and 4) Reduce the progression and promotion of cancer in vivo.
Some forms of cancer, for example, certain breast cancers and prostate
cancers, are hormone
dependent. In the test tube, melatonin inhibits the growth of breast tumor
cells, and in animals
blocks the growth of breast cancer. Melatonin has recently been demonstrated
to be a potent
antioxidant by scavenging highly reactive hydroxyl radicals, and in vitro
protects DNA from free
radical damage. This effect is concentration dependent. Antioxidant activity
may be one of the
ways that melatonin helps to prevent cancers. In animals, removal of the
pineal gland can
increase the growth of some cancers. Conversely, women with profound bilateral
blindness have
high melatonin levels and a significantly decreased incidence of cancer of the
breast, as described
in Hahn RA, Profound bilateral blindness and the incidence of breast cancer,
Epidemiology
1991;2:208-10.
Clinical studies have demonstrated that shift-workers who work part of, or the
whole of the night,
in a lighted environment may have increased rates of heart disease and cancer,
as described in
Kawachi I, et al., Prospective study of shift work and risk of coronary heart
disease in women,
Circulation 1995;92:3178-82 and Hansen J, Increased breast cancer risk among
women who
work predominantly at night, Epidemiology 2001;12:74-7.
CA 02497261 2005-02-28
WO 2004/021071 PCT/CA2003/001324
3
Two epidemiologic studies have determined a link between exposure to light at
night and an
increased risk of breast cancer. In one study described in Davis S, et al.,
Night shift work, light at
night, and risk of breast cancer, J Natl Cancer Inst 2001;93:1557-62 case
patients with breast
cancer (n = 813), aged 20-74 years, were compared with control subjects (n =
793) identified by
random-digit dialing and age matched. An in-person interview was used to
gather information
on sleep habits and bedroom lighting environment in the 10 years before
diagnosis and lifetime
occupational history. The authors found that breast cancer risk was increased
among subjects
who frequently did not sleep during the period of the night when melatonin
levels are typically at
their highest (OR = 1.14 for each night per week; 95% CI = 1.01 to 1.28). Risk
did not increase
with interrupted sleep accompanied by taming on a light. There was an
indication of increased
risk among subjects with the brightest bedrooms. Graveyard shiftwork was
associated with
increased breast cancer risk (OR = 1.6; 95% CI = 1.0 to 2.5), with a trend of
increased risk with
increasing years and with more hours per week of graveyard shift work (P
=.02). The results of
this study provided evidence that exposure to light at night may be associated
with the risk of
developing breast cancer. The authors speculated that exposure to light at
night may increase the
risk of breast cancer by suppressing the normal nocturnal production of
melatonin by the pineal
gland, which, in turn, could increase the release of estrogen by the ovaries.
Data from the Nurses Health Study was also analyzed to search for a link
between light at night
and breast cancer risk. The authors investigated the relationship between
breast cancer and
working on rotating night shifts during 10 years of follow-up in 78 562 women
from the Nurses'
Health Study, described in Schernhammer ES, et al., Rotating night shifts and
risk of breast
cancer in women participating in the nurses' health study, J Natl Cancer Inst
2001;93:1563-8.
Information was ascertained in 1988 about the total number of years during
which the nurses had
worked rotating night shifts of three or more days per month. From June 1988
through May
1999, 2441 incident breast cancer cases were documented. The authors observed
a moderate
increase in breast cancer risk among the women who worked 1-14 years or 15-29
years on
rotating night shifts (multivariate adjusted RR = 1.08 [95% CI = 0.99 to 1.18]
and RR = 1.08
[95% Cl = 0.90 to 1.30], respectively). The risk was further increased among
women who
worked 30 or more years on the night shift (RR = 1.36; 95% CI = 1.04 to 1.78).
The test for
trend was statistically significant (P =.02). They concluded that women who
work on rotating
night shifts with at least three nights per month, in addition to days and
evenings in that month,
appear to have a moderately increased risk of breast cancer after extended
periods of working
rotating night shifts.
CA 02497261 2005-02-28
WO 2004/021071 PCT/CA2003/001324
4
In all of the clinical studies, the adverse effect of light exposure at night
on cancer risk was
thought to act through suppression of melatonin levels. A recent study
examined the effects of
different wavelengths of light on melatonin suppression and phase shifting of
the salivary
melatonin rhythm in the human, described in Wright HR, and Lack LC, Effect of
light
wavelength on suppression and phase delay of the melatonin rhythm, Chronobiol
Int
2001;18:801-8. The wavelengths compared were 660 run (red), 595 nm (amber),
525 nm
(green), 497 nm (blue/green), and 470 nm (blue) and light of each wavelength
was administered
using light-emitting diodes equated for irradiance of 130 muW/cm2. Fifteen
volunteers
participated in all five wavelength conditions and a no light control
condition, with each
condition conducted over two consecutive evenings. Half-hourly saliva samples
were collected
from 19:00 to 02:00 on night 1 and until 01:00 on night 2. Light was
administered for the
experimental conditions on the first night only from midnight to 02:00.
Percentage melatonin
suppression on night 1 and dim light melatonin onset (DLMO) for each night
were calculated.
The shorter wavelengths of 470, 497, and 525 nm showed the greatest melatonin
suppression,
65% to 81%. The shorter wavelengths also showed the greatest DLMO delay on
night 2, ranging
from 27 to 36 min. There was much less suppression of melatonin by higher
wavelengths, such
as red or amber light.
In a rat model, exposure to light of different wavelengths also resulted in
similar findings
regarding melatonin suppression, as described in Honma S, et al., Light
suppression of nocturnal
pineal and plasma melatonin in rats depends on wavelength and time of day,
Neurosci Lett
1992;147:201-4. Effects of light on pineal gland and plasma melatonin were
examined in Wistar
and Long-Evans rats at the 4th hour into the dark phase (light off from 18.00
h to 06.00 h) using
lights of two different monochromatic wavelengths but with the same
irradiance. The green light
pulse (520 nm) given at 24.00 h suppressed the pineal and plasma melatonin to
the day-time level
for at least 2 h, while the red light (660 nm) pulse suppressed pineal
melatonin only transiently
and did not suppress the plasma melatonin at all.
Animal studies, in Beniashvili et al, Effect of light/dark regimen on N-
nitrosoethylurea-induced
transplacental carcinogenesis in rats. Cancer Left., 2001; Feb. 10; 163(l):51-
7, have shown that
constant exposure to light significantly promotes transplacental
carcinogenesis. Observational
studies have associated night-shift work with an increased risk of breast and
colorectal cancers as
shown in for example Tynes et al., Incidence of breast cancer in Norweigan
female radio and
telegraph operators. Cancer Causes Control. 1996 Mar; 7(2):197-204; Hansen,
J., Light at night,
CA 02497261 2005-02-28
WO 2004/021071 PCT/CA2003/001324
shiftwork, and breast cancer risk. J. Natl Cancer Inst. 2001 Oct 17;
93(20):1513-5; and
Schernhammer et al., Night-shift work and risk of colorectal cancer in the
nurses' health study. J
Natl. Cancer Inst. 2003 Jun 4;95(11):825-8. Furthermore, melatonin has been
shown to be a
free-radical scavenger and antioxidant, and conditions that involve free
radical damage may be
5 aggravated by light suppression of melatonin levels (Reiter, Potential
biological consequences of
excessive light exposure:melatonin suppression, DNA damage, cancer and
neurodegenerative
diseases. Neuroendocrinol Lett. 2002 Jul; 23 Suppl 2:9-13). These findings
suggest that shift-
workers may have an increased danger of developing various forms of cancer due
to a repetitive
exposure to light at night.
Therefore, studies in humans and in rats both demonstrated that different
wavelengths of light
during the dark phase suppress melatonin levels differentially. White light
and short wavelength
light (green and blue) suppress melatonin to the greatest degree, while longer
wavelengths of
light (eg. red) have little or no melatonin suppression. It is therefore
desirable to provide an
optical filter that selectively blocks light of a wavelength capable of
suppressing melatonin levels
in a human that can be used by people who are exposed to melatonin suppressing
light at peak
melatonin production times.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention may be better understood by the attached description and may be
further illustrated
by the figures, in which:
Figure 1 illustrates the technical characteristics of the yellow lenses
described in example 1;
Figures 2A-C illustrates the characteristic effects of bright and filtered
light on endogeneous
melatonin secretion by three male patients, as described in example 1;
Figures 2D-E illustrates the characteristic effects of bright and filtered
light on endogeneous
melatonin secretion by two female patients, as described in example 1; and
Figure 3 illustrates relative values of melatonin secretion during dim-light,
exposure to bright-
light and exposure to light protected by yellow lenses as described in example
1.
CA 02497261 2011-07-04
6
SUMMARY OF THE INVENTION
In a broad aspect the present invention provides a device for inhibiting
melatonin suppressing light.
The device includes a means for selectively blocking light of a wavelength
capable of suppressing
melatonin production in a human.
In one embodiment the present invention provides an optical filter, and the
use thereof, designed to
prevent melatonin suppression by light at night by preventing light of certain
wavelengths, known to
maximally suppress melatonin, from reaching the retina of the eye.
In another embodiment the present invention provides a lens, and the use
thereof, that includes an
optical filter that selectively blocks light of a wavelength capable of
suppressing melatonin production
in a human. The lens being suitable for use in eyewear for humans who are
exposed to melatonin
suppressing light at peak melatonin production times.
In another embodiment the present invention provides a lens having an optical
filter that is operable to
block light having a wavelength that suppresses melatonin production, and a
polarizing layer.
In another embodiment there is provided a device for inhibiting melatonin
suppression by light
comprising: means for selectively blocking more than 50 percent of incident
wavelengths of light
having a wavelength range less than at or about 530 nm, while transmitting
more than 50 percent of
non-blocked wavelengths of light, wherein the device inhibits the light-
induced suppression of
melatonin production by light exposure when used at night.
Other embodiments include the following:
A method for inhibiting melatonin suppression by light in a human comprising
providing the device
described above, more specifically an optical filter during peak melatonin
production times thereby
selectively blocking more than 50 percent of incident wavelengths of light
having a wavelength range
less than at or about 530 nm, while transmitting more than 50 percent of non-
blocked wavelengths of
light, the device being operable to selectively block light, having a
wavelength range less than at or
about 530 nm, from reaching the retina in a human for inhibiting melatonin
suppression by light.
CA 02497261 2011-07-04
6a
DETAILED DESCRIPTION OF THE INVENTION
This present invention may be accomplished by various means. The following
provides a definition
for some of the terms used in the specification
Eyewear is used as a broad term to encompass such items as eyeglasses,
goggles, contact lenses and
the like, that are used in connection with the eyes of a user to either
shield/protect the eyes from
harmful substances, for example chemicals in the context of goggles or to
enhance the eyesight of the
user, for example contact lenses. It will be understood that the term
"eyewear" is not limited to the
above examples, and describes any device used in connection with the eyes that
contains a viewing
window of sorts.
Melatonin suppressing light is light that has a wavelength "that suppresses
the production or secretion
of melatonin in a human. Melatonin suppressing light is preferably, but not
limited to, light having a
wavelength in the green spectrum.
Substantially transmitting, when used in terms of wavelength of light, is
defined as transmitting more
than 1 percent of the incident radiation at each and every wavelength.
CA 02497261 2005-02-28
WO 2004/021071 PCT/CA2003/001324
7
Substantially blocking, when used in terms of wavelength of light, is defined
as blocking over 50
percent of the incident wavelength at each and every wavelength.
As discussed above, in one embodiment the present invention provides a device
for inhibiting
melatonin suppressing light. The device has means for selectively blocking
light having a
wavelength capable of suppressing melatonin levels in a human. The means for
selectively
blocking light preferably blocks a sufficient amount of the light, having a
wavelength capable of
suppressing melatonin level, to result in the prevention of at least about 50%
of the melatonin
suppression. The device may be, but is not limited to, for example eyewear, a
lightbulb, a light
cover, a lens, or any other device that may be utilized for the purpose of
preventing light of
wavelengths that suppress melatonin levels in a human. In use, the device
prevents light of
wavelengths that suppress melatonin levels from reaching the retina of a
human, thereby
preventing suppression of melatonin levels in the human.
In another embodiment the present invention provides an optical filter that
selectively blocks
light of a wavelength capable of suppressing melatonin production in a human.
The optical filter
preferably blocks a sufficient amount of the light, having a wavelength
capable of suppressing
melatonin level, to result in the prevention of at least about 50% of the
melatonin suppression.
Another embodiment of the present invention provides a lens that includes an
optical filter that
selectively blocks light of a wavelength capable of suppressing melatonin
production in a human.
The lens being suitable for use in eyewear for humans who are exposed to
melatonin suppressing
light at peak melatonin production times. As will be understood by a person
skilled in the art, the
lens may be made from any material that is suitable to be used in eyewear,
examples of such
material include, but are not limited to, glass or plastic.
In another embodiment the present invention provides a lens having an optical
filter that is
operable to block light having a wavelength that suppresses melatonin
production in a human,
and a polarizing layer. The polarizing layer being operable to selectively
absorb reflected glare
in one direction. It will be understood by a person skilled in the art that
the polarizing layer may
have any form that is suitable to be used in a lens. For example, the
polarizing layer may be a
polarized film that can be laminated to the surface of the lens, such as PP 10
polarized lens
material produced by Polaroid. Other suitable embodiments of the polarizing
layer will be
known by a person skilled in the art.
CA 02497261 2005-02-28
WO 2004/021071 PCT/CA2003/001324
8
In a further embodiment the lens may also include an ultraviolet light
absorber laminated to at
least one side of the lens or the lens may be treated or coated with an ultra
violet filter such as an
ultra violet light blocking dye. The ultraviolet light absorber being operable
to absorb UV rays
and preferably operable to absorb 100% of harmful UV rays.
The embodiments described above provide a lens that is operable to prevent
light of certain
melatonin suppressive wavelengths from reaching the retina of the eye.
In another embodiment of the invention, an optical filter may be applied to
the surface of an
incandescent or fluorescent light bulb to block light of specific short
wavelengths from being
emitted.. The optical filter that is used preferably selectively blocks light
of a wavelength capable
of suppressing melatonin production in a human.
Another embodiment is the application of an optical filter, to block light of
specific short
wavelengths, into the semi-opaque lens of a nightlight. The optical filter
being capable of
selectively blocking light of a wavelength capable of suppressing melatonin
production in a
human.
Studies to date have shown that the incidence of breast cancer is increased in
night shift workers,
an effect attributed to suppression of the night melatonin secretion peak by
light exposure. The
present invention provides a lens that can be incorporated into eyewear that a
night shift worker
can wear in order to prevent the melatonin suppressing wavelengths from
reaching their retinas.
By preventing the melatonin suppressing light from reaching the retina,
melatonin will continue
to be produced thereby reducing the risks to the worker that are associated
with a lack of
melatonin production, for example reducing the possible risk of breast cancer.
An alternative embodiment of the present invention is a light cover for use in
conjunction with a
light source. The light cover may include an optical filter that is operable
to selectively block
light from the light source having a wavelength capable of suppressing
melatonin production in a
human. The cover being operable to releasably attach to the light source to
channel the light
emitted from the light source through the cover. It will be understood by a
person skilled in the
art that the cover may be any shape or form as long as it is operable to cover
the light source that
it is to be used with, for example if the light source is an oblong strip
light, then the cover is
preferably oblong and of a size that will fit around the light source to
contain the light source
therein. By containing the light source within the cover the light emitted
from the light source
CA 02497261 2005-02-28
WO 2004/021071 PCT/CA2003/001324
9
must be channeled through the cover, and therefore all light having a
wavelength capable of
suppressing melatonin production in a human will be blocked.
The light cover may also be permanently attached to the light source, for
example the light cover
may be a coating on the light source, or the light source may be manufactured
from a material
that selectively blocks light having a wavelength capable of suppressing
melatonin production in
a human.
An additional benefit of the invention may include the reduction of the
incidence and severity of
jet lag in travelers across multiple time zones where out of phase exposure to
light may disturb
the normal circadian rhythm of melatonin.
The following example illustrates one embodiment of the invention. It will be
understood that
the present invention is not limited to the example provided.
Example 1
A study was undertaken to measure the impact on melatonin production of one
type of yellow
lens. A yellow filter lens was provided that allowed selective exclusion of
all wavelengths below
530nm while maintaining relatively good color recognition and a visual light
transmittance in
daylight of approximately 63% and a visual light transmittance in nightlight
of approximately
73%. Figure 1 illustrates the technical characteristics of the lenses having
an edge at +/- 530nm,
and above 530nm filters out approximately 8% of longer wavelengths.
In the study a total of 6 healthy young males and 2 healthy young females
(mean age 22.5 1.5)
participated. The inclusion and exclusion criteria for this study were
implemented to discourage
biased data resulting from external factors. All subjects underwent a
psychiatric and sleep
assessment to rule out significant psychopathology and sleep disruption. All
subjects scored less
than 7 on the Epworth Sleepiness Scale as described in Johns, A new method for
measuring
daytime sleepiness. Sleep 1991 Dec; 14(6):540-5, and scored in the normal
range on the
Morningness/Eveningness questionnaire as described in Home and Ostberg, A self-
assessment
questionnaire to determine momingness-eveningness in human circadian rhythms.
Int. J.
Chronobiol. 1976; 4(2):97-110, a subjective measure of their circadian rhythm.
Subjects were
rejected if they had experienced sleep and circadian rhythm disorders,
excessive daytime
sleepiness, eye disease, depression, psychotic illness, a history of cancer,
or shift-work in the past
year.
CA 02497261 2005-02-28
WO 2004/021071 PCT/CA2003/001324
During the study, subjects were asked to stay awake overnight at a Sleep
Research Clinic for 3
non-consecutive nights over a two-week period. Prior to each night of the
study, subjects were
asked to complete a previous night sleep inventory (PNSI) to ensure that their
quality of sleep
was not deficient.
5 The first night, melatonin production measured (in saliva) under dim light
(<50 lx) conditions
established each individual's circadian profile of melatonin secretion,
unaffected by light
exposure. Saliva specimens provide a non-invasive and practical method for
melatonin
assessment with high validity as described in Gooneratne et al., The validity
and feasibility of
saliva melatonin assessment in the elderly. J. Pineal Res. 2003 Mar; 34(2):88-
94.
10 The Dim Light Melatonin Onset (DLMO) test, as described in Lewy et al, The
endogenous
melatonin profile as a marker for circadian phase position. J Biol Rhythms.
1999 Jun; 14(3):227-
36; Kayumov et al, Exogenous melatonin shifts dim light melatonin onset in
post-traumatic
delayed sleep phase syndrome. Sleep 2002; 25: 18, was used as a marker of
circadian phase, and
was the time of the first saliva melatonin level to cross the DLMO threshold.
The threshold was
defined as 20% of the maximum raw value of endogenous melatonin.
The subjects spent 12 hours awake from 20:00 h to 08:00h in the sleep
laboratory while hourly
data was collected. The results of the DLMO testing provided a baseline for
comparison of
melatonin levels during the other interventions.
The subjects were randomly assigned to wear the yellow filter lenses
incorporated into goggles
on either the second or third night. On the alternate night, the subjects were
exposed to the bright
light without wearing goggles. On all nights, 13 saliva samples were collected
at regular one-
hour intervals beginning at 20:00 h (8:00pm). Subjects were placed in a well
lit room (800 lx)
designed to mimic a shift-work environment. The exact luminescence of the
rooms was
determined using a luxometer.
Due to individual variability in DLMO and acute phase shifting effects of
light on melatonin
secretion profiles, the clock time was converted to circadian time (CT). For -
this purpose, the
beginning of melatonin production was referenced by designating the baseline
DLMO as CT 14,
as described in Ahmed et al, Phase response curve of low-intensity green light
in winter
depressives. Sleep Research 1995; 24: 508. This technique provided the ability
to compare the
hormonal status of each individual at the same circadian time in three
different conditions.
CA 02497261 2005-02-28
WO 2004/021071 PCT/CA2003/001324
11
Moreover, it was assumed that darkness is an ideal environment for maximum
melatonin
production and therefore, relative values of melatonin in light conditions
(with or without
goggles) compared to designated 100% production in the dark were used. Another
reason to use
relative values was the large interpersonal variability in absolute melatonin
levels since it is well
recognized that there are low and high melatonin secretors.
Repeated measures analysis of variance (MANOVA) was used to determine the
statistical
significance of melatonin values in the three different conditions.
Statistically significant results
detected by analysis of variance (p<.05) were further analyzed by using Tukey
post hoc paired
comparisons using the Statistical Package for the Social Sciences software
(SPSS, version 11.5,
for Windows.
Saliva specimens were collected using the Sali-SaverTM (ALPCO - American
Laboratory
Products Company, NH, USA). The Sali-SaverTM consists of a small cotton roll
that is placed
between the cheek and the gum for 3-5 min in order to collect saliva specimen
(up to 2 ml can be
collected at a time). Saliva specimens were. analyzed immediately after
collection of the last
sample. Saliva melatonin was determined by Direct Saliva Melatonin ELISA kit
from Buhlman
Laboratories (Allschwil, Switzerland). Aliquots of at least 200 l of
centrifuged saliva from each
collection time were used for the analysis. Saliva specimens from a given
subject were run with
the same assay kit. Quality control was assessed by using a low and high
melatonin standard
included in the kit. Assay functional sensitivity was 1.3 pg/ml, the maximum
infra-assay and
inter-assay coefficients of variability were 6.5% (n=12) and 11.3% (n=12),
respectively (in the
range of concentrations of melatonin between 1 and 81 pg/ml).
The study results showed that all subjects wearing yellow lenses exhibited a
melatonin secretion
profile similar to their dim light pattern throughout the night. In contrast,
bright light drastically
suppressed melatonin production. Exposure to bright light and filtered light
caused a phase delay
in endogenous melatonin secretion, although the latter condition induced a
less pronounced shift.
Figure 2A-E displays characteristic effects of bright and filtered light on
endogenous melatonin
secretion in 3 male subjects (Figures A-C) and 2 female subjects (Figures D
and E). The results
under the dim light condition (f) represent normal melatonin production. All
subjects
demonstrated preserved melatonin secretion in filtered light (c) similar to
the profile obtained in
dim light, although there was a noticeable phase delay under both light
conditions.
CA 02497261 2005-02-28
WO 2004/021071 PCT/CA2003/001324
12
Conversion of the clock time into circadian time reduced samples available for
analysis (from 13
to 8): pre-DLMO baselines and CT14 through CT20 melatonin levels. Analysis of
variance
(MANOVA) showed that suppression of melatonin levels at all data collection
points (except at
Pre-DLMO) did not occur when yellow lenses were worn (Pre- DLMO F=4.6, p>.05;
CT14
F=16.4, p<.0001; CT15 F=19.2, p<.0001; CT16 F=37.2, p<.0001; CT17 F=10.4,
p=.001; CT18
F=19.7, p<.0001; CT20 F=26.3, p<.0001). Figure 3 illustrates relative values
of melatonin
secretion during dim-light, exposure to bright light, and exposure to light
protected by yellow
lenses for the entire group.
The data illustrates that wearing light-filtering goggles to block wavelengths
less than 530nm
allows close to normal melatonin onset and peak secretion in subjects during
night-time exposure
to bright light.
While the invention has been described with reference to certain embodiments
thereof, it will be
understood that changes and modifications may be made by those of ordinary
skill in the art
within the scope and spirit of the following claims.
